Browse the evidence

Semax enhances neuroplasticity and cognitive function in aging by upregulating BDNF and modulating neurotransmitter systems, showing benefits in stroke recovery and cognitive decline.

Semax is a peptide that may improve brain health by increasing BDNF, a key factor in neuroplasticity. Russian studies suggest it can help stroke recovery and cognitive function, but it is not FDA-approved for these uses, and independent Western validation is lacking.

The American College of Sports Medicine (ACSM) acknowledges that lawful and ethical therapeutic use of anabolic-androgenic steroids (AAS) is now an accepted mainstream treatment for several clinical disorders.

Practitioners should recognize AAS as a legitimate treatment option for certain clinical conditions.

Long-term results with semaglutide and tirzepatide are approaching the success seen with bariatric surgery.

Practitioners should be aware of the effectiveness of semaglutide and tirzepatide in weight management.

Excessive consumption of sugars and refined starches, rather than saturated fat, is the primary dietary driver of atherogenic dyslipidemia and coronary heart disease risk in people with diabetes.

To reduce heart disease risk, prioritize reducing sugars and refined starches over reducing dietary fat. High carbohydrate intake drives the production of harmful small dense LDL particles, even if total cholesterol appears normal.

Short-term intensive insulin therapy can induce T2DM remission in newly diagnosed patients with high blood glucose levels (HbA1c ≥ 10% and FBG ≥ 11.1 mmol/L) by restoring beta-cell function.

If you were just diagnosed with Type 2 Diabetes and your blood sugar is very high, your doctor might suggest a short course of insulin. This isn't forever; it's used to quickly lower your blood sugar and give your pancreas a break so it can start working better on its own. This is most effective for people recently diagnosed.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) induce significant weight loss and metabolic improvement in patients with Bardet-Biedl syndrome (BBS), a genetic obesity syndrome previously resistant to standard pharmacotherapy.

If you have Bardet-Biedl Syndrome and struggle with severe obesity despite trying other medications, GLP-1 receptor agonists (like semaglutide or liraglutide) combined with dietary changes may be a viable treatment option. This case showed a 33% weight loss and normalized blood sugar, suggesting that genetic obesity is not necessarily resistant to these specific hormonal therapies.

Intentional weight loss in individuals with high adipose tissue stores of persistent organic pollutants (POPs) may lead to long-term cognitive decline due to the mobilization of these neurotoxic chemicals into the circulation and brain.

If you are overweight and have high exposure to environmental toxins (like certain pesticides or industrial chemicals), be aware that rapid or intensive weight loss might temporarily increase the levels of these chemicals in your blood. While weight loss is generally good for heart and metabolic health, this specific mechanism suggests that slow, steady weight loss might be preferable to minimize the spike in circulating toxins, especially if you have existing cardiovascular issues. Focus on reducing external exposure to POPs (dietary sources) alongside weight loss.

Metabolically healthy obesity may confer a lower risk of dementia compared to lean obesity because healthy adipose tissue safely stores neurotoxic persistent organic pollutants (POPs), preventing them from reaching the brain.

For those with obesity, maintaining metabolic health (normal blood sugar, blood pressure, and lipids) is crucial. Healthy fat tissue may act as a 'sink' for environmental toxins, potentially protecting the brain. However, this does not negate the benefits of weight loss if you are metabolically unhealthy. Focus on metabolic health markers and reducing exposure to environmental toxins.

Retatrutide, a triple-hormone receptor agonist (GLP-1/GIP/Glucagon), can cause intractable, secretory diarrhea and acute kidney injury, particularly when used off-label via unregulated online sources with unestablished dosing protocols.

If you are using retatrutide or similar GLP-1 agonists obtained from online sources, be aware that dosing is not standardized and risks are higher. Intractable diarrhea and kidney injury are serious potential side effects. Seek regulated medical care for weight loss management to ensure safe dosing and monitoring.

Higher baseline levels of Myostatin are associated with significant functional decline (Gait Speed and 6MWD) in older adults with sarcopenia, while inflammatory markers (IL-6, hsCRP) show less consistent or no correlation with functional decline.

While not yet a standard clinical test, high Myostatin levels may predict functional decline in sarcopenic older adults. In contrast, common inflammatory markers (CRP, IL-6) did not correlate with functional decline in this study, suggesting they may not be the primary drivers of functional loss in this population.

GLP-1 receptor agonists may enhance the weight loss and metabolic benefits of adjustable gastric banding (AGB) by mimicking the hormonal effects of more invasive surgeries like Roux-en-Y gastric bypass.

Research suggests that combining GLP-1 medications with Adjustable Gastric Banding might improve weight loss results. However, this is still experimental, and you should discuss the risks (like pancreatitis) and benefits with your surgeon.

GLP-1 agonists (e.g., tirzepatide) and metformin show promise in improving asthma outcomes in obese patients by enhancing insulin sensitivity and reducing airway inflammation, though specific FDA approvals for obesity-associated asthma are lacking.

If you have asthma and obesity, discuss with your doctor whether metabolic treatments like GLP-1 agonists might help your asthma symptoms, especially if you have insulin resistance. While not yet approved specifically for asthma, they may improve lung function and reduce inflammation.

High cardiorespiratory fitness induced by prior exercise training likely confers innate immune protection against SARS-CoV-2 by attenuating proinflammatory cytokine storms.

Maintain high cardiorespiratory fitness through regular moderate-to-vigorous aerobic exercise. While this may help mitigate severe inflammatory responses to respiratory viruses like SARS-CoV-2, it is not a substitute for standard preventive measures like vaccination and hygiene.

GLP-1 agonists like semaglutide may reduce the exposure (efficacy) of ALK tyrosine kinase inhibitors like alectinib due to delayed gastric emptying.

Be aware that taking semaglutide might reduce how much cancer medication your body absorbs. However, slow titration (starting low and going slow) may help mitigate this interaction.

Global sodium consumption above 2.0 g/day is attributable to 1.65 million cardiovascular deaths annually, with the majority occurring in low- and middle-income countries.

Reducing your sodium intake to below 2.0 g/day can significantly lower your risk of cardiovascular death. This is especially important if you live in a low- or middle-income country, where the burden is highest. Focus on reducing processed foods and added salt.

Low-carbohydrate and ketogenic diets are not currently recommended for the treatment of Type 1 Diabetes due to lack of long-term safety data and risk of complications like DKA and growth deficits in children.

For Type 1 Diabetes, low-carb and ketogenic diets are not currently recommended by major guidelines due to safety concerns like DKA and unknown long-term effects on growth. While some patients may see short-term improvements in glucose control, the risks are significant. Consult your healthcare provider before considering any drastic dietary changes.

GLP-1 analogs are widely used in Saudi Arabia for diabetes management and show some weight loss efficacy, but there is no trial data for their use in obesity-only patients in the country.

GLP-1 analogs are used in Saudi Arabia for diabetes, but there is no specific trial data for obesity-only patients. Use with caution and monitor weight loss.

Obesity in IBD patients is associated with altered pharmacokinetics of biological therapies, leading to faster drug clearance, lower trough concentrations, and potentially reduced treatment efficacy.

If you take biological injections for IBD and are obese, your body might process the drug faster than a lean person's, making it less effective. You should discuss this with your doctor. They might monitor your drug levels more closely or adjust your dose to ensure you get the full benefit of the treatment.

Semaglutide (2.4 mg once weekly) promotes adipose tissue browning and mitochondrial biogenesis via the AMPK/SIRT1/PGC1α/UCP1 axis, enhancing energy expenditure and thermogenesis, although this mechanism is primarily established in preclinical rodent models rather than confirmed in humans.

Semaglutide 2.4mg weekly leads to ~15% weight loss. While it likely works partly by boosting metabolism (browning fat) via complex hormonal pathways seen in animals, the primary driver for you is reduced appetite. Do not rely on the 'browning' mechanism to explain your results; focus on the proven appetite suppression.

Dual and triple incretin receptor agonists (e.g., tirzepatide, retatrutide) show potential for greater cardiovascular risk factor reduction than single GLP-1RAs, though definitive cardiovascular outcome trial results are pending.

Newer multi-incretin agonists (like tirzepatide) are showing superior improvements in blood sugar, weight, and blood pressure compared to single GLP-1RAs. While their specific impact on heart attacks and strokes is still being studied, they represent a promising next step for cardiovascular risk reduction in diabetes.

Resistance exercise-induced lactate accumulation may promote skeletal muscle hypertrophy through multiple mechanisms including lactate-stimulated testosterone production, histone lactylation, and activation of satellite cell pathways via GPR81/ERK1/2 signaling, although direct evidence in humans is currently insufficient.

While mechanical tension is king, incorporating training styles that generate high lactate (e.g., higher reps, shorter rest) may offer additional hypertrophic benefits via metabolic signaling. However, do not rely on this as a primary driver, as human evidence is currently weak compared to mechanical load.

A single-administration self-boosting microneedle patch delivering semaglutide sustains therapeutic plasma levels and induces weight loss in rats for one month, effectively simulating four separate weekly subcutaneous injections.

This research proposes a microneedle patch that delivers semaglutide (a weight-loss drug) through the skin. Instead of getting a shot every week, you apply a small patch once, and it releases the medication slowly over four weeks. In rats, this worked just as well as getting four separate shots. While promising for reducing pain and improving adherence, this is still experimental technology tested only on animals, not yet available for human use.

Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.

Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.

GLP-1 agonist administration in Type 1 Diabetes patients can precipitate Euglycemic Diabetic Ketoacidosis (EDKA) by suppressing gluconeogenesis and glycogenolysis, masking the hyperglycemia typically required for DKA diagnosis.

If you have Type 1 Diabetes and are taking a GLP-1 agonist (like Wegovy or Ozempic), be aware that you can develop Diabetic Ketoacidosis (DKA) even if your blood sugar looks normal. This is called Euglycemic DKA. If you experience nausea, vomiting, or abdominal pain, do not assume it is just a side effect or that your insulin is working. Check your blood ketones and seek medical attention if they are elevated, as standard DKA treatments (high insulin, no dextrose) may be dangerous without dextrose support.